DRREDDY.NS Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 geg. 2024 @ 09:59):

Stats
Dzisiejszy wolumen	22 612.00
Średni wolumen	374 113
Kapitalizacja rynkowa	967.71B
EPS	INR0 ( 2024-05-06 )
Następna data zysków	( INR76.04 ) 2024-07-23
Last Dividend	INR40.00 ( 2023-07-11 )
Next Dividend	INR0 ( N/A )
P/E	17.37
ATR14	INR2.59 (0.04%)

Wolumen Korelacja

Długi: -0.32 (neutral)

Krótki: -0.78 (moderate negative)

Signal:(60.564) Neutral

Dr. Reddy's Laboratories Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Dr. Reddy's Laboratories Korelacja - Waluta/Towar

0.48
( neutral )

-0.35
( neutral )

0.59
( weak )

-0.61
( weak negative )

0.64
( weak )

Dr. Reddy's Laboratories Finanse

Annual	2023
Przychody:	INR279.16B
Zysk brutto:	INR163.61B (58.61 %)
EPS:	INR334.02

FY	2023
Przychody:	INR279.16B
Zysk brutto:	INR163.61B (58.61 %)
EPS:	INR334.02

FY	2022
Przychody:	INR245.88B
Zysk brutto:	INR169.30B (68.86 %)
EPS:	INR271.43

FY	2022
Przychody:	INR214.39B
Zysk brutto:	INR113.84B (53.10 %)
EPS:	INR142.08

Financial Reports:

No articles found.

Dr. Reddy's Laboratories Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR60.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR40.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Dr. Reddy's Laboratories Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 7.29 - Increase likely (45.73%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR2.50	2003-08-08
Last Dividend	INR40.00	2023-07-11
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	23	--
Total Paid Out	INR363.00	--
Avg. Dividend % Per Year	0.62%	--
Score	3.8	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	7.29
Div. Directional Score	9.40	--

Next Divdend (Est)
(2024-07-01)

INR42.96 Estimate 3.12 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.80

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR40.00	1.93%
2019	INR20.00	0.77%
2020	INR25.00	0.87%
2021	INR25.00	0.48%
2022	INR60.00	1.24%
2023	INR40.00	0.94%
2024	INR0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
RBLBANK.NS	Dividend Junior	2023-08-18	Sporadic	8	0.25%
KOTAKBANK.NS	Dividend Junior	2023-08-04	Annually	23	0.04%
EMUDHRA.NS	Dividend Knight	2023-06-22	Annually	3	0.21%
AJANTPHARM.NS	Dividend Knight	2023-08-04	Annually	23	0.57%
TASTYBITE.NS	Dividend Junior	2023-07-14	Annually	8	0.01%
NEWGEN.NS	Dividend Knight	2023-06-20	Annually	7	2.26%
ICIL.NS	Dividend Junior	2023-08-11	Annually	10	0.77%
CASTROLIND.NS	Dividend Knight	2023-08-08	Semi-Annually	22	4.14%
SAKUMA.NS	Dividend Junior	2023-09-22	Annually	19	0.33%
LTIM.NS	Dividend Knight	2023-07-10	Semi-Annually	9	0.87%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.199	1.500	6.01	9.02	[0 - 0.5]
returnOnAssetsTTM	0.144	1.200	5.21	6.25	[0 - 0.3]
returnOnEquityTTM	0.213	1.500	8.75	10.00	[0.1 - 1]
payoutRatioTTM	0.119	-1.000	8.81	-8.81	[0 - 1]
currentRatioTTM	2.58	0.800	2.09	1.669	[1 - 3]
quickRatioTTM	1.684	0.800	4.80	3.84	[0.8 - 2.5]
cashRatioTTM	0.0740	1.500	-0.700	-1.050	[0.2 - 2]
debtRatioTTM	0.0517	-1.500	9.14	-10.00	[0 - 0.6]
interestCoverageTTM	59.84	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	271.47	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	106.71	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.0714	-1.500	9.71	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.586	1.000	3.57	3.57	[0.2 - 0.8]
operatingProfitMarginTTM	0.240	1.000	7.21	7.21	[0.1 - 0.6]
cashFlowToDebtRatioTTM	2.26	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.720	0.800	8.53	6.82	[0.5 - 2]
Total Score				11.51

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	17.38	1.000	8.35	0	[1 - 100]
returnOnEquityTTM	0.213	2.50	9.19	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	106.71	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.688	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	271.47	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.119	1.500	8.81	-8.81	[0 - 1]
pegRatioTTM	1.393	1.500	4.04	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.162	1.000	8.45	0	[0.1 - 0.5]
Total Score				7.29

Dr. Reddy's Laboratories Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.